Table 3. degs Involved in Transport Process, ccm, and Regulation of Gene Expression.
| Gene ID | “LOW” versus “HIGH” | LA1920 versus LA0716 | Annotation | ||
|---|---|---|---|---|---|
| Log2FC | FDR | Log2FC | FDR | ||
| Transporters | |||||
| Sopen04g023150 | −1.16 | 2.00E−02 | −1.82 | 4.40E−09 | ABC transporter F family member |
| Sopen01g047950 | −1.68 | 2.10E−02 | −2.82 | 3.30E−04 | ABC transporter G family member |
| Sopen04g005380 | 3.19 | 2.80E−08 | 2.8 | 6.50E−04 | ABC transporter G family member |
| Sopen12g034820 | 4.37 | 2.10E−12 | 3.47 | 4.00E−06 | Pleiotropic drug resistance protein1-like (ABC transporter G family) |
| Sopen03g001870 | 4.52 | 1.10E−32 | 4 | 3.60E−09 | ABC transporter B family member |
| Central carbon metabolism | |||||
| Sopen07g006810 | 5.01 | 6.70E−12 | 3.63 | 4.30E−04 | RUBISCO small subunit |
| Sopen08g020180 | 2.11 | 1.90E−10 | 2.18 | 2.30E−07 | NADP-dependent malic enzyme |
| Sopen12g026980 | 2.72 | 1.80E−09 | 1.21 | 3.40E−04 | Glutathione S-transferase |
| Sopen01g042050 | 3.39 | 1.30E−09 | 2.76 | 3.10E−06 | Sugar transporter ERD6-like |
| Selected transcription factors | |||||
| Sopen05g008450a | 4.9 | 1.3E−21 | 4.15 | 6.3E−10 | AP2 domain |
| Sopen12g021250a | 3.9 | 4.4E−15 | 2.88 | 5.6E−06 | AP2 domain |
| Sopen03g036630a | 3.13 | 1.5E−12 | 2.71 | 3.8E−07 | AP2 domain |
| Sopen10g031080a | 2.68 | 5.5E−12 | 2.53 | 3E−07 | Homeobox associated leucine zipper |
| Sopen06g024660a | 2.88 | 1.9E−09 | 4.02 | 9.8E−11 | Myb-like DNA-binding domain |
| Sopen08g028640a | 3.54 | 1.5E−07 | 3.57 | 3.6E−08 | AP2 domain |
| Sopen02g021600a | 1.79 | 5.6E−05 | 2.07 | 6.4E−05 | Myb-like DNA-binding domain |
| Sopen01g037680a | 1.8 | 9E−04 | 1.39 | 2.1E−02 | TCP family transcription factor |
| Sopen03g037210a | 1.65 | 1.1E−03 | 2.62 | 9.7E−05 | Helix–loop–helix DNA-binding domain |
Log2FC indicates log2 (fold-change). Positive and negative log2FC values indicate higher and lower expression levels, respectively, in high-acylsugar–producing accessions. 2.00E−02 = 2.00 × 10−02.
Transcription factor genes were selected based on their response to imazapyr treatment (see Table 5).